In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. The Company records a loss contingency if the information available indicates that it is probable that a liability has been incurred at the date of the financial statements and the amount of loss can be reasonably estimated. As of December 31, 2020, in the opinion of management, no claims meet the criteria to record a loss contingency.

The following table reflects the Company’s future non-cancellable minimum purchase commitments for inventory as of December 31, 2020:

	Total		2021		2022		2023		2024		2025		Thereafter
Purchase commitments	$	84,094	$	84,094	$	—	$	—	$	—	$	—	$	—
Total	$	84,094	$	84,094	$	—	$	—	$	—	$	—	$	—

In 2018, the Company signed an agreement with Rose Lifescience Inc. (“Rose”) for distribution and marketing of product in Quebec in exchange for a minimum fee of $384 per annum for an initial term of five years, and agreed to purchase the lesser of 2,000 Kg per year or 40% of the production of Cannabis at a rate of 115% of cost of goods sold from the Rose facility. In September 2020, the Company signed an amendment to this agreement under which the Company is no longer obligated to purchase product from Rose nor pay the minimum fee. Instead, the amendment requires the Company to make approximately 40,000 kilograms equivalent Tilray product available in the province of Quebec through 2023 for Rose for sale and pay Rose a compensation fee based on net revenue sold in Quebec for an estimated compensation fee of approximately $8.0 million through 2023. As there is no firm commission fee commitment, it is excluded from the above schedule. Compensation fee expense is recorded as incurred.

In 2018, the Company entered into a Product and Trademark License Agreement with Docklight LLC, a related party (refer to Note 25), to use certain intellectual property rights in exchange for payment of royalty depending upon specified percentage of licensed product net sales. As the purchase commitment is an undeterminable variable amount, it is excluded from the above schedule.

The Company has payments on the convertible notes (refer to Note 14), ABG finance liability (refer to Note 4), the Senior Facility (refer to Note 15), and Portugal construction purchase commitments as follows:

	Total		2021		2022		2023		2024		2025		Thereafter
Convertible notes, principal and interest	$	319,535	$	13,893	$	13,893	$	291,749	$	—	$	—	$	—
Senior Facility, principal and interest		56,683		5,302		51,381		—		—		—		—
ABG finance liability		7,500		1,500		1,500		1,500		1,500		1,500	$	—
Portugal construction commitments		2,778		2,778		—		—		—		—		—
Total	$	386,496	$	23,473	$	66,774	$	293,249	$	1,500	$	1,500	$	—

In the event the Company consummates the announced merger with Aphria Inc., the Company has agreed to pay its financial advisor a non-refundable $9,000 transaction fee on the date of closing.